Divi's Laboratories

NSE: DIVISLAB · Pharma

₹6,383.65

▼ -1.79%

HOLD

Illustrative research · not investment advice Demo price · quote unavailable · Fundamentals and research: sample dataset (30 Oct 2026)

Price chart

Illustrative price history · not actual market candles

A. Company overview

Leading API and custom synthesis manufacturer.

Market cap

₹5,90,91,803 Cr

Industry / Sector

Pharma

Segments

Website

Visit ↗

Generic APIsCustom SynthesisNutraceuticals

B. Fundamental analysis (illustrative)

Revenue growth

+16.83%

Net profit growth

+11.93%

Operating margin

15.78%

EBITDA margin

19.42%

ROE

29.57%

ROCE

34.51%

Debt / Equity

0.89

EPS

₹270.84

Operating cash flow

₹13,951 Cr

Working capital

₹9,291 Cr

5-year revenue & profit (₹ Cr)

C. Financial statements (illustrative)

₹ Cr	FY22	FY23	FY24	FY25	FY26
Revenue	86,556	92,410	1,01,964	1,10,845	1,16,138
EBITDA	18,266	19,093	18,757	21,514	22,552
Net profit	11,416	11,933	11,723	13,446	14,095
EPS (₹)	189.59	211.26	232.92	254.59	276.26

D. Valuation analysis

P/E

23.57

P/B

3.34

EV/EBITDA

33.35

Price/Sales

2.16

EPS

₹270.84

Dividend yield

0.49%

Peer comparison — Pharma

Company	CMP	P/E	P/B	ROE	D/E
Divi's Laboratories	6,383.65	23.57	3.34	29.57%	0.89
Sun Pharmaceutical	1,781.5	55.43	3.1	22.33%	0.13
Dr. Reddy's Laboratories	1,276.25	54.23	4.39	18.22%	1.24
Cipla	1,489.5	36.69	3.85	10.69%	1.42

E. Technical analysis

RSI (14)

55.65

MACD

8.4

Support

₹6,064.47

Resistance

₹6,766.67

Volume

81,60,739

Illustrative technical charts · not actual market history

Candlestick (last 50 sessions)

Price with 50-DMA & 200-DMA, volume

Fibonacci retracement levels

23.6% · ₹6395.37

38.2% · ₹6223.29

50.0% · ₹6084.22

61.8% · ₹5945.14

F. Shareholding pattern

Promoter12.74%

FII35.89%

DII28.93%

of which Mutual Funds13.55%

Public22.44%

G. SWOT analysis

Strengths

Established position in Pharma
ROE of 29.57% in demo data

Weaknesses

Limited pricing power in some segments
Cyclical exposure

Opportunities

Domestic demand growth
Expansion in Generic APIs

Threats

Regulatory changes
Competitive intensity

Illustrative template points for demonstration.

H. Research conclusion

Financial strength

Moderate leverage to monitor

Business quality

High capital efficiency

Valuation

Reasonable valuation

Growth

Sales growth of 16.83%

Risk assessment

Low risk

Overall

Illustrative HOLD opinion · target ₹6,748.43 · stop loss ₹5,560.77

I. Corporate actions

Dividend history (₹/share)

Year	Dividend
FY22	25.02
FY23	26.9
FY24	28.78
FY25	30.65
FY26	32.53

Bonus, splits & announcements

Bonus history: none in demo dataset
Stock split history: none in demo dataset
Board meeting for quarterly results — demo announcement